Novadip's $22 Million B Round for Skeletal Tissue Therapies Includes HK Investor

Novadip Biosciences of Belgium raised $22 million in a Series B round from global investors including CR-CP Life Science Fund of Hong Kong. Novadip is a clinical stage company developing products to regenerate impaired skeletal tissue. Its proprietary 3M3 platform is a 3-dimensional, extracellular matrix that uses adipose-derived stem cells to deliver growth factors and miRNAs that mimic natural healing. The company's lead candidate is an autologous bone product aimed at diseases that include congenital pseudarthrosis of the tibia (CPT), a rare pediatric disease. More details.... Share this with colleagues: // //